Repros Therapeutics Surges 60% Following Encouraging Study Results

Shares of Repros Therapeutics Inc (NASDAQ: RPRX), a nano-cap biopharmaceutical company that focuses on the treatment of hormonal and reproductive system disorders, is surging higher by 60 percent.

Repros Therapeutics reported after Tuesday's close that patients receiving 6 and 12 mg doses of Proellex achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids. The findings were part of a small Phase 2b study.

Repros Therapeutics believes Prollex "represents a significant advantage over GnRH agonists and antagonists in the treatment of uterine fibroids."

The company added it plans on requesting an end of Phase 2 meeting with the U.S. Food and Drug Administration and will discuss plans for a Phase 3 trial.

The stock traded recently at $0.81, up 59 percent in the pre-market session.